The neurobiology of bipolar disorder: Identifying targets for specific agents and synergies for combination treatment

International Journal of Neuropsychopharmacology

Volumn 17, Issue 7, 2014, Pages 1039-1052

  Andreazza, Ana C ^a,b   Young, L Trevor ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Bipolar disorder; cellular signalling; mitochondrial dysfunction and oxidative stress; neurobiology

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOLAMINE; CYCLIC AMP;

BIPOLAR DISORDER; CACNA1C GENE; CELL DAMAGE; CELL FUNCTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC SYSTEM; GENE; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; NEUROBIOLOGY; NEUROPATHOLOGY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; ANIMAL; BRAIN; DRUG COMBINATION; DRUG EFFECTS; MITOCHONDRION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

ANIMALS; BIPOLAR DISORDER; BRAIN; DRUG THERAPY, COMBINATION; HUMANS; MITOCHONDRIA; OXIDATIVE STRESS;

EID: 84901398313     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713000096     Document Type: Review

References (129)

1. Abdalla DS, Monteiro HP, Oliveira JA, Bechara EJ (1986) Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clin Chem 32:805-807.
2. Abdolmaleky HM, Cheng KH, Faraone SV, Wilcox M, Glatt SJ, Gao F, Smith CL, Shafa R, Aeali B, Carnevale J, Pan H, Papageorgis P, Ponte JF, Sivaraman V, Tsuang MT, Thiagalingam S (2006) Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet 15:3132-3145.
3. Altamura AC, Serati M, Albano A, Paoli RA, Glick ID, Dell'Osso B (2011) An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses. Eur Arch Psychiatry Clin Neurosci 261:489-508.
4. Andreazza AC, Cassini C, Rosa AR, Leite MC, de Almeida LM, Nardin P, Cunha AB, Cereser KM, Santin A, Gottfried C, Salvador M, Kapczinski F, Goncalves CA (2007) Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 41:523-529.
5. Andreazza AC, Kapczinski F, Kauer-Sant'Anna M, Walz JC, Bond DJ, Gonçalves CA, Young LT, Yatham LN (2009) 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci 34:263-271.
6. Andreazza AC, Kauer-Sant'anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, Yatham LN (2008) Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 111:135-144.
7. Andreazza AC, Shao L, Wang JF, Young LT (2010) Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 67:360-368.
8. Anggard E, Jonsson LE, Hogmark AL, Gunne LM (1973) Amphetamine metabolism in amphetamine psychosis. Clin Pharmacol Ther 14:870-880.
9. Arts B, Simons CJ, Os J (2013) Evidence for the impact of the CACNA1C risk allele rs1006737 on 2-year cognitive functioning in bipolar disorder. Psychiatr Genet 23:41-42.
10. Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B, Schulze TG, Cichon S, Rietschel M, Nöthen MM, Georgi A, Schumacher J, Schwarz M, Abou Jamra R, Höfels S, Propping P, Satagopan J, Detera-Wadleigh SD, Hardy J, McMahon FJ (2008) A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 13:197-207.
11. Beitelshees AL, Navare H,Wang D, Gong Y, Wessel J, Moss JI, Langaee TY, Cooper-DeHoff RM, Sadee W, Pepine CJ, Schork NJ, Johnson JA (2009) CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet 2:362-370.
12. Benes FM, Kwok EW, Vincent SL, Todtenkopf MS (1998) A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol Psychiatry 44:88-97.
13. Benes FM, Matzilevich D, Burke RE, Walsh J (2006) The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol Psychiatry 11:241-251.
14. Benes FM, Todtenkopf MS, Kostoulakos P (2001a) GluR5,6,7 subunit immunoreactivity on apical pyramidal cell dendrites in hippocampus of schizophrenics and manic depressives. Hippocampus 11:482-491.
15. Benes FM, Vincent SL, Todtenkopf M (2001b) The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects. Biol Psychiatry 50:395-406.
16. Berk M, Dodd S, Kauer-Sant'anna M, Malhi GS, Bourin M, Kapczinski F, Norman T (2007) Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand (Suppl.) 116:41-49.
17. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yücel M, Gama CS, Dodd S, Dean B, Magalhães PV, Amminger P, McGorry P, Malhi GS (2011) Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 35:804-817.
18. Bezchlibnyk Y, Young LT (2002) The neurobiology of bipolar disorder: focus on signal transduction pathways and the regulation of gene expression. Can J Psychiatry 47:135-148.
19. Bezchlibnyk YB, Sun X, Wang JF, MacQueen GM, McEwen BS, Young LT (2007) Neuron somal size is decreased in the lateral amygdala nucleus of subjects with bipolar disorder. J Psychiatry Neurosci 32:203-210.
20. Bigos KL, Mattay VS, Callicott JH, Straub RE, Vakkalanka R, Kolachana B, Hyde TM, Lipska BK, Kleinman JE, Weinberger DR (2010) Genetic variation in CACNA1C affects brain circuitries related to mental illness. Arch Gen Psychiatry 67:939-945.
21. Bowley MP, Drevets WC, Ongür D, Price JL (2002) Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 52:404-412.
22. Brennand KJ, Simone A, Tran N, Gage FH (2012) Modeling psychiatric disorders at the cellular and network levels. Mol Psychiatry 17:1239-1253.
23. Burdick KE, Funke B, Goldberg JF, Bates JA, Jaeger J, Kucherlapati R, Malhotra AK (2007) COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance. Bipolar Disord 9:370-376.
24. Byerley W, Badner JA (2011) Strategies to identify genes for complex disorders: a focus on bipolar disorder and chromosome 16p. Psychiatr Genet 21:173-182.
25. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud J, Egan MF, Kleinman JE, Weinberger DR (2004) Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in post mortem human brain. Am J Hum Genet 75:807-821.
26. Cheng R, Juo SH, Loth JE, Nee J, Iossifov I, Blumenthal R, Sharpe L, Kanyas K, Lerer B, Lilliston B, Smith M, Trautman K, Gilliam TC, Endicott J, Baron M (2006) Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder. Mol Psychiatry 11:252-260.
27. Chiu CT, Chuang DM (2011) Neuroprotective action of lithium in disorders of the central nervous system. Zhong Nan Da Xue Xue Bao Yi Xue Ban 36:461-476.
28. Cipriani A, Rendell J, Geddes JR (2011) Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis. J Psychopharmacol 24:1729-1738.
29. Clay HB, Sillivan S, Konradi C (2010) Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci 29:311-324.
30. Coyle JT, Duman RS (2003) Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38:157-160.
31. De Jongh KS, Murphy BJ, Colvin AA, Hell JW, Takahashi M, Catterall WA (1996) Specific phosphorylation of a site in the full-length form of the alpha 1 subunit of the cardiac L-type calcium channel by adenosine 3′,5′- cyclic monophosphatedependent protein kinase. Biochemistry 35:10392-10402.
32. de Sousa RT, van de Bilt MT, Diniz BS, Ladeira RB, Portela LV, Souza DO, Forlenza OV, Gattaz WF, Machado-Vieira R (2011) Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett 494:54-56.
33. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793-802.
34. Dickinson D, Elvevåg B (2009) Genes, cognition and brain through a COMT lens. Neuroscience 164:72-87.
35. Dubovsky SL, Thomas M, Hijazi A, Murphy J (1994) Intracellular calcium signalling in peripheral cells of patients with bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci 243:229-234.
36. Eastwood SL, Harrison PJ (2010) Markers of glutamate synaptic transmission and plasticity are increased in the anterior cingulate cortex in bipolar disorder. Biol Psychiatry 67:1010-1016.
37. El Khoury A, Petterson U, Kallner G, Aberg-Wistedt A, Stain-Malmgren R (2002) Calcium homeostasis in long-term lithium-treated women with bipolar affective disorder. Prog Neuropsychopharmacol Biol Psychiatry 26:1063-1069.
38. Emamghoreishi M, Li PP, Schlichter L, Parikh SV, Cooke R, Warsh JJ (2000) Associated disturbances in calcium homeostasis and G protein-mediated cAMP signaling in bipolar I disorder. Biol Psychiatry 48:665-673.
39. Farris W, Leissring MA, Hemming ML, Chang AY, Selkoe DJ (2005) Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry 44:6513-6525.
40. Fatemi SH, Folsom TD (2007) Catechol-O-methyltransferase gene regulation in rat frontal cortex. Mol Psychiatry 12:322-323.
41. Fernandes BS, Gama CS, Ceresér KM, Yatham LN, Fries GR, Colpo G, de Lucena D, Kunz M, Gomes FA, Kapczinski F (2011) Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 45:995-1004.
42. Ferreira MA et al. (2008) Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 40:1056-1058.
43. Freland L, Beaulieu JM (2012) Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol Neurosci 5:14.
44. Gergerlioglu HS, Savas HA, Bulbul F, Selek S, Uz E, YumruM (2007) Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment. Prog Neuropsychopharmacol Biol Psychiatry 31:697-702.
45. Gigante AD, Young LT, Yatham LN, Andreazza AC, Nery FG, Grinberg LT, Heinsen H, Lafer B (2010) Morphometric post-mortem studies in bipolar disorder: possible association with oxidative stress and apoptosis. Int J Neuropsychopharmacol 14:1075-1089.
46. Ginsberg SD, Hemby SE, Smiley JF (2012) Expression profiling in neuropsychiatric disorders: emphasis on glutamate receptors in bipolar disorder. Pharmacol Biochem Behav 100:705-711.
47. Goldstein BI, Fagiolini A, Houck P, Kupfer DJ (2009a) Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord 11:657-662.
48. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS (2009b) Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 70:1078-1090.
49. Gould TD (2006) Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications. Expert Opin Ther Targets 10:377-392.
50. Gould TD, Quiroz JA, Singh J, Zarate CA, Manji HK (2004) Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 9:734-755.
51. Green EK, Hamshere M, Forty L, Gordon-Smith K, Fraser C, Russell E, Grozeva D, Kirov G, Holmans P, Moran JL, Purcell S, Sklar P, Owen MJ, O'Donovan MC, Jones L, WTCCC5, Jones IR, Craddock N (2012) Replication of bipolar disorder susceptibility alleles and identification of two novel genome-wide significant associations in a new bipolar disorder case-control sample. Mol Psychiatry. Advance online publication. doi:10.1038/mp.2012.142.
52. Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, O'Donovan C, Alda M (2002) Is response to prophylactic lithium a familial trait? J Clin Psychiatry 63:942-947.
53. Group PGCBDW (2011) Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 43:977-983.
54. Guidotti A, Auta J, Chen Y, Davis JM, Dong E, Gavin DP, Grayson DR, Matrisciano F, Pinna G, Satta R, Sharma RP, Tremolizzo L, Tueting P (2011) Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology 60:1007-1016.
55. Halbreich U, Endicott J (1981) Possible involvement of endorphin withdrawal or imbalance in specific premenstrual syndromes and postpartum depression. Med Hypotheses 7:1045-1058.
56. Halliwell B, Gutteridge JMC (2007) Free radicals in biology and medicine. Oxford: Clarendon Press.
57. Iwamoto K, Bundo M, Kato T (2005) Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet 14:241-253.
58. Jonsson G, Fuxe K, Hokfelt T (1972) On the catecholamine innervation of the hypothalamus, with special reference to the median eminence. Brain Res 40:271-281.
59. Jope RS, Roh MS (2006) Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 7:1421-1434.
60. Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PV, Kauer-Sant'Anna M, Klamt F, Pasquali MA, Quevedo J, Gama CS, Post R (2010) A systemic toxicity index developed to assess peripheral changes in mood episodes. Mol Psychiatry 15:784-786.
61. Kapczinski F, Frey BN, Vieta E (2011) Sleep and circadian rhythm disturbances in bipolar disorder: an urgent need for objective assessment and systematic follow-up. J Clin Psychiatry 72:724.
62. Kato T (2008) Molecular neurobiology of bipolar disorder: a disease of 'mood-stabilizing neurons'? Trends Neurosci 31:495-503.
63. Kempton MJ, Ruberto G, Vassos E, Tatarelli R, Girardi P, Collier D, Frangou S (2009) Effects of the CACNA1C risk allele for bipolar disorder on cerebral gray matter volume in healthy individuals. Am J Psychiatry 166:1413-1414.
64. Kim HW, Rapoport SI, Rao JS (2010) Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol Dis 37:596-603.
65. King TD, Jope RS (2005) Inhibition of glycogen synthase kinase-3 protects cells from intrinsic but not extrinsic oxidative stress. Neuroreport 16:597-601.
66. Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S (2004) Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 61:300-308.
67. Konradi C, Sillivan SE, Clay HB (2012) Mitochondria, oligodendrocytes and inflammation in bipolar disorder: evidence from transcriptome studies points to intriguing parallels with multiple sclerosis. Neurobiol Dis 45:37-47.
68. Krupitsky EM, Burakov AM, Romanova TN, Grinenko NI, Grinenko AY, Fletcher J, Petrakis IL, Krystal JH (2001) Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists. Neuropsychopharmacology 25:936-947.
69. Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N (2002) Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 20:171-175.
70. Kupfer DJ, Angst J, Berk M, Dickerson F, Frangou S, Frank E, Goldstein BI, Harvey A, Laghrissi-Thode F, Leboyer M, Ostacher MJ, Sibille E, Strakowski SM, Suppes T, Tohen M, Yolken RH, Young LT, Zarate CA (2011) Advances in bipolar disorder: selected sessions from the 2011 International Conference on Bipolar Disorder. Ann NY Acad Sci 1242:1-25.
71. Lachman HM, Morrow B, Shprintzen R, Veit S, Parsia SS, Faedda G, Goldberg R, Kucherlapati R, Papolos DF (1996) Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet 67:468-472.
72. Lai JS, Zhao C, Warsh JJ, Li PP (2006) Cytoprotection by lithium and valproate varies between cell types and cellular stresses. Eur J Pharmacol 539:18-26.
73. Langan C, McDonald C (2009) Neurobiological trait abnormalities in bipolar disorder. Mol Psychiatry 14:833-846.
74. Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, Kupfer DJ (2012) Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord 141:1-10.
75. Lee SY, Chen SL, Chen SH, Huang SY, Tzeng NS, Chang YH, Wang CL, Lee IH, Yeh TL, Yang YK, Lu RB (2011) The COMT and DRD3 genes interacted in bipolar I but not bipolar II disorder. World J Biol Psychiatry 12:385-391.
76. Lee SY, Chen SL, Wang YS, Chang YH, Huang SY, Tzeng NS, Lee IH, Yeh TL, Yang YK, Lu RB (2013) COMT and BDNF interacted in bipolar II disorder not comorbid with anxiety disorder. Behav Brain Res 237:243-248.
77. Lelli-Chiesa G, Kempton MJ, Jogia J, Tatarelli R, Girardi P, Powell J, Collier DA, Frangou S (2011) The impact of the Val158Met catechol-O- methyltransferase genotype on neural correlates of sad facial affect processing in patients with bipolar disorder and their relatives. Psychol Med 41:779-788.
78. Liang MH, Wendland JR, Chuang DM (2008) Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling. Mol Cell Neurosci 37:440-453.
79. Liu Y et al. (2011) Meta-analysis of genome-wide association data of bipolar disorder and major depressive disorder. Mol Psychiatry 16:2-4.
80. Lopez-Larson MP, DelBello MP, Zimmerman ME, Schwiers ML, Strakowski SM (2002) Regional prefrontal gray and white matter abnormalities in bipolar disorder. Biol Psychiatry 52:93-100.
81. McCullumsmith RE, Kristiansen LV, Beneyto M, Scarr E, Dean B, Meador-Woodruff JH (2007) Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res 1127:108-118.
82. Machado-Vieira R, Andreazza AC, Viale CI, Zanatto V, Cereser V, da Silva Vargas R, Kapczinski F, Portela LV, Souza DO, Salvador M, Gentil V (2007) Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 421:33-36.
83. Machado-Vieira R, Ibrahim L, Henter ID, Zarate CA (2012) Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav 100:678-687.
84. Machado-Vieira R, Pivovarova NB, Stanika RI, Yuan P, Wang Y, Zhou R, Zarate CA, Drevets WC, Brantner CA, Baum A, Laje G, McMahon FJ, Chen G, Du J, Manji HK, Andrews SB (2011) The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder. Biol Psychiatry 69:344-352.
85. Mallinger AG, Thase ME, Haskett R, Buttenfield J, Luckenbaugh DA, Frank E, Kupfer DJ, Manji HK (2008) Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms. Bipolar Disord 10:856-866.
86. Mamdani F, Alda M, Grof P, Young LT, Rouleau G, Turecki G (2008) Lithium response and genetic variation in the CREB family of genes. Am J Med Genet B Neuropsychiatr Genet 147B:500-504.
87. Manaye KF, Lei DL, Tizabi Y, Dávila-García MI, Mouton PR, Kelly PH (2005) Selective neuron loss in the paraventricular nucleus of hypothalamus in patients suffering from major depression and bipolar disorder. J Neuropathol Exp Neurol 64:224-229.
88. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zarkov Z (2011) Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68:241-251.
89. Murray J, Taylor SW, Zhang B, Ghosh SS, Capaldi RA (2003) Oxidative damage to mitochondrial complex I due to peroxynitrite: identification of reactive tyrosines by mass spectrometry. J Biol Chem 278:37223-37230.
90. Napolitano A, Crescenzi O, Pezzella A, Prota G (1995) Generation of the neurotoxin 6-hydroxydopamine by peroxidase/H2O2 oxidation of dopamine. J Med Chem 38:917-922.
91. Nishioka M, Bundo M, Koike S, Takizawa R, Kakiuchi C, Araki T, Kasai K, Iwamoto K (2012) Comprehensive DNA methylation analysis of peripheral blood cells derived from patients with first-episode schizophrenia. J Hum Genet. Advance online publication. doi:10.1038/jhg.2012.140.
92. Nohesara S, Ghadirivasfi M, Mostafavi S, Eskandari MR, Ahmadkhaniha H, Thiagalingam S, Abdolmaleky HM (2011) DNA hypomethylation of MB-COMT promoter in the DNA derived from saliva in schizophrenia and bipolar disorder. J Psychiatr Res 45:1432-1438.
93. Nurnberger JI Jr., Gershon ES, Simmons S, Ebert M, Kessler LR, Dibble ED, Jimerson SS, Brown GM, Gold P, Jimerson DC, Guroff JJ, Storch FI (1982) Behavioral, biochemical and neuroendocrine responses to amphetamine in normal twins and 'well-state' bipolar patients. Psychoneuroendocrinology 7:163-176.
94. Ongur D, Drevets WC, Price JL (1998) Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 95:13290-13295.
95. Perlis RH, Smoller JW, Ferreira MA, McQuillin A, Bass N, Lawrence J, Sachs GS, Nimgaonkar V, Scolnick EM, Gurling H, Sklar P, Purcell S (2009) A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry 166:718-725.
96. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T (2007) Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 90:397-406.
97. Rajkowska G (2003) Depression: what we can learn from postmortem studies. Neuroscientist 9:273-284.
98. Rajkowska G, Halaris A, Selemon LD (2001) Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 49:741-752.
99. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, Wagh UV, Debsikdar VB, Mahadik SP (2003) Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 121:109-122.
100. Rowe MK, Wiest C, Chuang DM (2007) GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev 31:920-931.
101. Rybakowski JK (2011) Lithium in neuropsychiatry: a 2010 update. World J Biol Psychiatry 12:340-348.
102. Rybakowski JK, Czerski P, Dmitrzak-Weglarz M, Kliwicki S, Leszczynska-Rodziewicz A, Permoda-Osip A, Skibinska M, Suwalska A, Szczepankiewicz A, Hauser J (2012) Clinical and pathogenic aspects of candidate genes for lithium prophylactic efficacy. J Psychopharmacol 26:368-373.
103. Rybakowski JK, Skibinska M, Suwalska A, Leszczynska-Rodziewicz A, Kaczmarek L, Hauser J (2011) Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene and response to lithium prophylaxis in bipolar patients. Hum Psychopharmacol 26:168-171.
104. Rybakowski JK, Suwalska A, Skibinska M, Szczepankiewicz A, Leszczynska-Rodziewicz A, Permoda A, Czerski PM, Hauser J (2005) Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry 38:166-170.
105. Savas HA, Gergerlioglu HS, Armutcu F, Herken H, Yilmaz HR, Kocoglu E, Selek S, Tutkun H, Zoroglu SS, Akyol O (2006) Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J Biol Psychiatry 7:51-55.
106. Schulze TG (2010) Genetic research into bipolar disorder: the need for a research framework that integrates sophisticated molecular biology and clinically informed phenotype characterization. Psychiatr Clin North Am 33:67-82.
107. Schulze TG, Akula N, Breuer R, Steele J, Nalls MA, Singleton AB, Degenhardt FA, Nöthen MM, Cichon S, Rietschel M, McMahon FJ, Study TBG (2012) Molecular genetic overlap in bipolar disorder, schizophrenia, and major depressive disorder. World J Biol Psychiatry. Advance online publication. doi:10.3109/15622975.2012.662282.
108. Scott LJ et al. (2009) Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. Proc Natl Acad Sci USA 106:7501-7506.
109. Sears C, Markie D, Olds R, Fitches A (2011) Evidence of associations between bipolar disorder and the brain-derived neurotrophic factor (BDNF) gene. Bipolar Disord 13:630-637.
110. Selek S, Savas HA, Gergerlioglu HS, Bulbul F, Uz E, YumruM (2008) The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord 107:89-94.
111. Shifman S, Bronstein M, Sternfeld M, Pisanté A, Weizman A, Reznik I, Spivak B, Grisaru N, Karp L, Schiffer R, Kotler M, Strous RD, Swartz-Vanetik M, Knobler HY, Shinar E, Yakir B, Zak NB, Darvasi A (2004) COMT: a common susceptibility gene in bipolar disorder and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 128B:61-64.
112. Silverstone T, Cookson J (1983) Examining the dopamine hypotheses of schizophrenia and of mania using the prolactin response to antipsychotic drugs. Neuropharmacology 22:539-541.
113. Sklar P et al. (2008) Whole-genome association study of bipolar disorder. Mol Psychiatry 13:558-569.
114. Sklar P et al. (2011) Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 43:977-983.
115. Smith EN et al. (2009) Genome-wide association study of bipolar disorder in European American and African American individuals. Mol Psychiatry 14:755-763.
116. Soeiro-de-Souza MG, Post RM, de Sousa ML, Missio G, do Prado CM, Gattaz WF, Moreno RA, Machado-Vieira R (2012) Does BDNF genotype influence creative output in bipolar I manic patients? J Affect Disord 2:181-186.
117. Sun X, Wang JF, Tseng M, Young LT (2006) Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. J Psychiatry Neurosci 31:189-196.
118. Suwalska A, Sobieska M, Rybakowski JK (2010) Serum brain-derived neurotrophic factor in euthymic bipolar patients on prophylactic lithium therapy. Neuropsychobiology 62:229-234.
119. Toker L, Belmaker RH, Agam G (2012) Gene-expression studies in understanding the mechanism of action of lithium. Expert Rev Neurother 12:93-97.
120. Uemura T, Green M, Corson TW, Perova T, Li PP, Warsh JJ (2011) Bcl-2 SNP rs956572 associates with disrupted intracellular calcium homeostasis in bipolar I disorder. Bipolar Disord 13:41-51.
121. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39:44-84.
122. Vawter MP, Tomita H, Meng F, Bolstad B, Li J, Evans S, Choudary P, Atz M, Shao L, Neal C, Walsh DM, Burmeister M, Speed T, Myers R, Jones EG, Watson SJ, Akil H, Bunney WE (2006) Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders. Mol Psychiatry 11:615, 663-679.
123. Wang JF (2007) Defects of mitochondrial electron transport chain in bipolar disorder: implications for mood-stabilizing treatment. Can J Psychiatry 52:753-762.
124. Wang JF, Shao L, Sun X, Young LT (2009) Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 11:523-529.
125. Weinshilboum RM, Otterness DM, Szumlanski CL (1999) Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 39:19-52.
126. Yin H, Zhu M (2012) Free radical oxidation of cardiolipin: chemical mechanisms, detection and implication in apoptosis, mitochondrial dysfunction and human diseases. Free Radic Res 46:959-974.
127. Zarate CA, Manji HK (2008) Bipolar disorder: candidate drug targets. Mt Sinai J Med 75:226-247.
128. Zhang D et al. (2009) Singleton deletions throughout the genome increase risk of bipolar disorder. Mol Psychiatry 14:376-380.
129. Zhou X, Tang W, Greenwood TA, Guo S, He L, Geyer MA, Kelsoe JR (2009) Transcription factor SP4 is a susceptibility gene for bipolar disorder. PLoS ONE 4: e5196.